Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pulmonary valve stenosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Pulmonary valve stenosis. Displaying page 1 of 1.
    EudraCT Number: 2016-002015-17 Sponsor Protocol Number: 2016-002015-17 Start Date*: 2017-03-10
    Sponsor Name:Odense University Hospital
    Full Title: Low-flow Low-gradient Aortic Stenosis – Diagnostic Usefullness of Ivabradine
    Medical condition: Aortic valve stenosis with reduced ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10002918 Aortic valve stenosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001676-21 Sponsor Protocol Number: P141102 Start Date*: 2016-12-19
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Anti-Thrombotic Strategy to Lower All Cardiovascular and Neurologic Ischemic and Hemorrhagic Events after Trans-Aortic Valve Implantation for Aortic Stenosis: The ATLANTIS trial
    Medical condition: Patients who underwent a clinically successful TAVI procedure.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10047065 - Vascular disorders 10002906 Aortic stenosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002580-85 Sponsor Protocol Number: 3d Start Date*: 2005-08-08
    Sponsor Name:Rigshospitalet
    Full Title: Acute haemodynanic effects of Treatment with ACE inhibitores in patients with severe Aortic Stenosis
    Medical condition: Aortic valve stenosis is a reduction of the aortic valve orifice to a degree where emptying of the left ventricule is compromised. The two major causes for aortic valve stenosis is calcific valve d...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001975-30 Sponsor Protocol Number: BAY59-7939/17938 Start Date*: 2016-01-12
    Sponsor Name:Bayer AG
    Full Title: Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc ...
    Medical condition: Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oral-anticoagulant) may reduce this risk, without increasing...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10002916 Aortic valve replacement PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) NO (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001425-26 Sponsor Protocol Number: REDOX19032019 Start Date*: 2019-07-04
    Sponsor Name:Thoraxcentrum Erasmus MC
    Full Title: Rotterdam Edoxaban Leaflet Evaluation in Patients after Transcatheter Aortic Valve Implantation
    Medical condition: aortic stenosis
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003975-38 Sponsor Protocol Number: TERPAH-001 Start Date*: 2007-11-22
    Sponsor Name:Ergonex Pharma GmbH
    Full Title: Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective P...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) NL (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001071-30 Sponsor Protocol Number: V1 Start Date*: 2010-01-21
    Sponsor Name:Medical University Vienna- Dept. of Pediatric Hemostaselology
    Full Title: Aspirin Resistance in Children after Interventional Cardiac Catheterization: The ARC Study
    Medical condition: children after interventional cardiac catheterization.
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018763-42 Sponsor Protocol Number: 2008CV17 Start Date*: 2010-07-14
    Sponsor Name:University of Dundee
    Full Title: Do Phosphodiesterase 5 Inhibitors Improve Exercise Capacity in COPD Patients with Pulmonary Hypertension?
    Medical condition: Chronic obstructive pulmonary disease Pulmonary hypertension (secondary to chronic obstructive pulmonary disease)
    Disease: Version SOC Term Classification Code Term Level
    10009033 Contains LLT
    10037406 Contains LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001675-37 Sponsor Protocol Number: Lis-Safe Start Date*: 2012-07-24
    Sponsor Name:Sinoxa Pharma GmbH
    Full Title: A Prospective, Open-label, Exploratory Study to Investigate the Safety, Efficacy, and Haemodynamics of Lisuride Subcutaneous Infusion as Add-on to Conventional Treatment in Patients with Pulmonary ...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000801-50 Sponsor Protocol Number: TDE-PH-302 Start Date*: 2007-02-19
    Sponsor Name:United Therapeutics Corporation
    Full Title: A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arteria...
    Medical condition: Idiopathic or Familial pulmonary arterial hypertension (PAH), including PAH associated with: 1) Appetite suppressant/toxin use, or 2) Repaired congenital systemic-to-pulmonary shunts (repaired ≥...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FR (Completed) BE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001613-33 Sponsor Protocol Number: BRIDGE Start Date*: 2014-05-13
    Sponsor Name:Thoraxclinic at the University of Heidelberg
    Full Title: Iloprost for Bridging to Heart Transplantation in Patients with Pulmonary Hypertension and Left Heart Failure
    Medical condition: Pulmonary Hypertension and Left Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10024106 Left heart failure LLT
    16.1 100000004855 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004863-41 Sponsor Protocol Number: SIPHT-001 Start Date*: 2006-10-04
    Sponsor Name:Dept. of Internal Medicine II, University Hospital Giessen
    Full Title: Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension (Shorttitle: SIPHT) Double-blind, randomized, prospe...
    Medical condition: Modified NYHA class II or III patients with Pulmonary Hypertension (PH), ICD: 416.9
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020787 Hypertension pulmonary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000800-17 Sponsor Protocol Number: TDE-PH-301 Start Date*: 2007-02-15
    Sponsor Name:United Therapeutics Corporation
    Full Title: A 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin...
    Medical condition: Idiopathic or Familial pulmonary arterial hypertension (PAH), including PAH associated with: 1) Appetite suppressant use, or 2) Repaired congenital systemic-to-pulmonary shunts (repaired ≥ 5 yea...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037400 Pulmonary hypertension PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) NL (Completed) AT (Completed) FR (Completed) BE (Completed) IT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004631-31 Sponsor Protocol Number: REM-PH-416 Start Date*: 2012-03-13
    Sponsor Name:United Therapeutics Corp.
    Full Title: A 16 Week, Open Label, Multi-Centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin® Therapy in Subjects with Pul...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10065151 Idiopathic pulmonary arterial hypertension LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10065152 Familial pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003621-24 Sponsor Protocol Number: MG-101-01 Start Date*: 2008-05-29
    Sponsor Name:MondoGEN AG
    Full Title: Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Pe...
    Medical condition: Pulmonary arterial hypertension (PAH) due to idiopathic pulmonary arterial hypertension (IPAH), familial PAH or PAH associated with connective tissue diseases (CTD) (e.g. systemic sclerosis, system...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    9.1 10065151 Idiopathic pulmonary arterial hypertension LLT
    9.1 10065152 Familial pulmonary arterial hypertension LLT
    9.1 10065150 Associated with pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003242-34 Sponsor Protocol Number: 67103 Start Date*: 2005-11-21
    Sponsor Name:National Institutes of Neurological Disorders: Stroke
    Full Title: Secondary Prevention of Small Subcortical Strokes
    Medical condition: Secondary prevention of small subcortical strokes
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10063751 Ministroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001853-89 Sponsor Protocol Number: CLI-043 Start Date*: 2006-07-07
    Sponsor Name:Vion Pharmaceuticals, Inc
    Full Title: A phase II study of Cloretazine for elderly patients with de novo poor risk acute myelogenous leukemia.
    Medical condition: Acute Myelogenous Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000324-34 Sponsor Protocol Number: APD356-G000-401 Start Date*: 2014-09-10
    Sponsor Name:Eisai Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Long-Term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Even...
    Medical condition: Obese and overweight patients with cardiovascular (CV) disease and/or multiple CV risk factors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004784-58 Sponsor Protocol Number: MRI-0143 Start Date*: 2007-06-22
    Sponsor Name:University of Leuven
    Full Title: Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohn’s disease
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 13:28:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA